Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Tenon Medical (TNONW) Change in Accured Expenses (2021 - 2025)

Historic Change in Accured Expenses for Tenon Medical (TNONW) over the last 5 years, with Q3 2025 value amounting to $499000.0.

  • Tenon Medical's Change in Accured Expenses rose 30619.83% to $499000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $327000.0, marking a year-over-year increase of 16160.0%. This contributed to the annual value of -$171000.0 for FY2024, which is 7272.73% down from last year.
  • Per Tenon Medical's latest filing, its Change in Accured Expenses stood at $499000.0 for Q3 2025, which was up 30619.83% from $55000.0 recorded in Q2 2025.
  • Over the past 5 years, Tenon Medical's Change in Accured Expenses peaked at $2.8 million during Q4 2022, and registered a low of -$1.1 million during Q3 2022.
  • For the 5-year period, Tenon Medical's Change in Accured Expenses averaged around $162368.4, with its median value being $20000.0 (2021).
  • Examining YoY changes over the last 5 years, Tenon Medical's Change in Accured Expenses showed a top increase of 660000.0% in 2024 and a maximum decrease of 164444.44% in 2024.
  • Tenon Medical's Change in Accured Expenses (Quarter) stood at $258000.0 in 2021, then surged by 974.81% to $2.8 million in 2022, then plummeted by 100.65% to -$18000.0 in 2023, then tumbled by 1644.44% to -$314000.0 in 2024, then surged by 258.92% to $499000.0 in 2025.
  • Its Change in Accured Expenses was $499000.0 in Q3 2025, compared to $55000.0 in Q2 2025 and $87000.0 in Q1 2025.